Market Intelligence, Clinical Progress, and High-Purity Reagents for Butyrylcholinesterase-Focused Therapeutics in Addiction Medicine, Alzheimer's Disease, and Chemical Defense.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BCHE (Butyrylcholinesterase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BCHE Recombinant Protein (Wild-Type & Mutants: A328W/Y332G, G117H/G198A) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View BCHE Products |
| Gene Delivery | BCHE Promise-ORF / Lentivirus Full-length ORF with Kozak sequence for stable cell lines and gene therapy research. |
View BCHE Products |
| Benchmark Ab | Anti-BCHE Recombinant Rabbit mAb (Clone 1C10) High-affinity capture antibody for PK/PD, ELISA, and western blot. |
View BCHE Products |
| Validator | BCHE siRNA Set (3 target-specific sequences) For knockdown verification and assay specificity control. |
View BCHE Products |
| Counter-Screen (Selectivity) | ACHE Recombinant Protein (Human/Mouse/Rhesus) Essential off-target liability assay for BCHE vs ACHE selectivity. Mass Spec Verified. |
View ACHE Products |
| Pathway Partner A | APP (Amyloid Precursor Protein) BCHE binds amyloid beta; co-target for Alzheimer's validation. |
View APP Products |
| Pathway Partner B | CHRNA7 (Neuronal Nicotinic Receptor α7) BCHE regulates α7-nAChR signaling; relevant for cognitive function assays. |
View CHRNA7 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ACHE vs BCHE Selectivity Screening (Safety) | Human ACHE & BCHE recombinant proteins (>95% purity) with sequence-verified native glycosylation for parallel IC50 determination. Same expression system (HEK293) ensures fair comparison. |
| Mutant Enzyme Kinetics (Cocaine Hydrolase / OP Scavenger) | WT vs mutant panel (A328W/Y332G, G117H/G198A) expressed in HEK293 for high-precision kinetic assays. Sequence verified for catalytic triad integrity. Theoretical MW confirmed. |
| Bioscavenger Efficacy Validation | HEK293 expressed proteins ensure critical native glycosylation needed for enzyme stability and long circulation. |
| Lack of Pharmacokinetic Controls | Anti-BCHE recombinant detection antibody included for PK/PD quantification. Clinical Benchmark Antibodies included. |
| False Positives in Cell Assays | Validated BCHE siRNA Set for target-specific knockdown and specificity checks. |
Trend: Live BCHE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The BCHE therapeutic landscape is bifunctional, driving two distinct R&D streams. In neurodegenerative diseases, particularly severe Alzheimer's Disease (AD), BCHE inhibitors are gaining traction as BCHE activity increases during disease progression, unlike ACHE. Conversely, recombinant BCHE is being actively developed as an exogenous prophylactic bioscavenger against organophosphate nerve agents, and its mutant forms are engineered as high-efficiency therapies for cocaine toxicity. The race for catalytic efficiency is intensifying, with protein engineering focused on enhancing cocaine hydrolase activity (kcat/Km > 10^9 M^-1 min^-1) while maintaining circulatory stability. As first-generation cocaine hydrolase variants (e.g., PEGylated mutants) enter Phase I trials, the next wave of R&D targets blood-brain barrier penetrance for CNS indications and half-life extension strategies (PEGylation, Fc-fusion, AAV gene therapy).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Engineered Enzyme (Cocaine Hydrolase) | Therapeutic Technologies Inc, University of Kentucky, NIDA-funded programs | Cocaine Addiction / Overdose | Catalytic efficiency screening: Need high-purity WT and mutant proteins (A328W/Y332G) with verified active sites. |
| Recombinant Enzyme (Bioscavenger) | DARPA/US DoD, PharmAthene (historical), PharmaJet | Organophosphate Poisoning Prophylaxis (Nerve agents) | OP binding kinetics: Need engineered mutants (G117H/G198A) and native glycosylated BCHE for stability. |
| Small Molecule Inhibitors (BCHE-Selective) | Novartis, Janssen, Academic Biotechs, Eisai | Alzheimer's Disease (late-stage) | Selectivity assay: Need highly pure BCHE and ACHE from same host for IC50 ratio determination. |
| Gene Therapy (AAV-BCHE) | InterveXion (historical), Academic consortia | Cocaine addiction (sustained), Genetic Deficiency | Cell line construction: Need lentiviral ORF for stable BCHE-expressing cell models prior to AAV development. |